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Immunology
Vesicular stomatitis virus glycoprotein is necessary for H-2-
restricted lysis of infected cells by cytotoxic T lymphocytes
(antigen recognition/viral immunity/temperature-sensitive mutants/cell surface antigens)
ARTHUR H. HALE, OWEN N. WITTE, DAVID BALTIMORE, AND HERMAN N. EISEN
Department of Biology and Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139
Contributed by Herman N. Eisen, December 5,1977
ABSTRACT Vesicular stomatitis virus (VSV) elicited cyto-
toxic thymus-derived lymphocytes (CTLs) in mice of the BALB/c
and three congenic strains (BALB.b, BALB.k, BALB.HTG). CTL
lysis of VSV-infected fibroblasts from the four strains was re-
stricted by the target cells' major histocompatibility complex
(H-2). Target cells were also infected with two temperature-
sensitive mutants of VSV, tsM and tsG in which, respectively,
the viral matrix protein and glycoprotein are not expressed at
390 (restrictive temperature) on the infected cell's surface
membrane. At the restrictive temperature, cells infected with
wild-type VSV or tsM were lysed by CTLs, but cells infected
with tsG were not. The requirement for the glycoprotein on the
target cell was also evident from the ability of antisera to the
glycoprotein to block completely CTL lysis of VSV-infected
cells.
Lysis of cells with newly acquired foreign surface antigens by
cytotoxic thymus-derived (T) lymphocytes (CTLs) probably
plays a central role in host resistance to many viral infections
and perhaps also in resistance to tumors. The specific attack of
CTLs on syngeneic target cells has recently been shown to be
governed by the "H-2 restriction" rule: i.e., to serve as an ef-
fective target for CTLs, a cell must have on its surface both the
same antigen and the same products of the major histocompa-
tibility complex (called H-2 in the mouse) as the cells that
originally stimulated development of the CTLs (1). Cross-
reactions among antigens and among products of the major
histocompatibility complex probably account for the occasional
instances in which this rule appears to be relaxed (2).
H-2 restriction in the killing of virus-infected target cells may
result either from a physical interaction between a major his-
tocompatibility product and a viral product to form a joint
antigen or form a requirement for dual recognition by the CTL
of both the H-2 antigen and the viral antigen (1). Whatever the
reason, it has thus far proven difficult to inhibit CTL killing
with soluble antigens (ref. 3; D. Inbar, A. H. Hale, V. Igras, and
H. N. Eisen, unpublished data). Therefore, the competition
assays with soluble antigens that have been so useful in studying
the antigenic determinants recognized by antibodies have not
been fruitful in studying the nature of antigen recognition by
CTLs.
To provide an alternative analysis of the antigens recognized
by CTLs we have developed a model system in which genetic
manipulation of a viral antigen is possible and the antigen is
easily purified. We chose vesicular stomatitis virus (VSV) be-
cause it specifies a single surface glycoprotein, the G protein,
which has been purified and partially characterized (4, 5).
Moreover, there are temperature sensitive (ts) mutants available
in most of the viral genes (4, 5). The known ts mutants of G
protein act after the first glycosylation step and prevent intra-
cellular transport of the protein to the cell surface (6, 7).
We show here that killing of VSV-infected cells by immune
syngeneic CTLs is H-2 restricted. Expression of the G protein
on the cell surface is necessary for killing because, at the non-
permissive temperature, cells infected with VSV containing a
ts lesion in G protein are not killed by otherwise competent
CTLs.
EXPERIMENTAL PROCEDURES
Mice. Female congenic mice of the following strains (H-2K
and H-2D alleles in parentheses) were produced in the Mas-
sachusetts Institute of Technology Center for Cancer Research
and used at 6-8 weeks of age: BALB/c (dd), BALB.b (bb),
BALB.k (kk), and BALB.HTG (db).
Cell Culture. Mouse L cells, originally derived from C3H
mice (H-2k haplotype), and baby hamster kidney (BHK) cells
were grown in suspension spinner culture at 370 in minimal
Eagle's medium with 7% heat-inactivated fetal calf serum
(Gibco). P388D1, a macrophage-like cell line derived from
DBA/2 mice (H-2d haplotype) (8, 9), was grown in spinner
culture at 370 in Dulbecco's modified Eagle's medium. Fi-
broblastic cell lines were derived as described by Todaro and
Green (10) from 17- to 18-day embryos of BALB/c and three
congenic strains (BALB.k, BALB.b, and BALB.HTG); these
lines were maintained in Dulbecco's modified Eagle's medium
with 10% calf serum at 370 (humidified atmosphere, 6%
C02/94% air). They were passaged 26-36 times before use.
Virus. Stocks were prepared by infecting baby hamster
kidney cells (4 X 105 cells per ml) with twice-plaque-purified
VSV Indiana (11, 12) at a multiplicity of 0.1. Virus was purified
away from defective particles and concentrated by sucrose
gradient centrifugation and sedimentation (13). The ts mutants
were tsM301 (III), called here tsM because it is defective in
VSV matrix (M) protein, and tsM501 (V), called here tsG be-
cause it is defective in G protein (6, 7).
Immunization. Mice were injected intraperitoneally or in-
travenously with various amounts of wild-type virus inactivated
in 20% sucrose in phosphate-buffered saline (8.0 g of NaCl, 0.2
g of KCl, 1.8 g of Na2HPO4-7H20, and 0.2 g of KH2PO4 in 1
liter, pH 7.4) with ultraviolet light to a final titer of 102-103
plaque-forming units (PFU).
Preparation of Effector Cells. Spleen and peritoneal exudate
cells (PECs) were used as effectors in cytotoxicity assays. These
cells were harvested and freed of erythrocytes as described
(14).
Abbreviations: CTLs, cytotoxic T lymphocytes; VSV, vesicular sto-
matitis virus; G, VSV glycoprotein; ts, temperature sensitive; M, VSV
matrix protein; PFU, plaque-forming units determined on L cells; PEC,
peritoneal exudate cell
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Preparation of Targets. P388D1 was plated at 0.5-1 X 104
cells per well and 3T3 fibroblasts were plated at 1-2 X 103 cells
per well in tissue culture plates (6-mm diameter wells, Linbro
Scientific, Inc., Hamden, CT) and incubated for 24-36 hr be-
fore infection with VSV (multiplicity of infection, 10-25). Four
hours later, the cells were labeled by incubating them for 1.5
hr with 5lCr (Na25ICrO4 at 1 mCi/ml, 25 Al per well, New
England Nuclear); then they were washed, and effector cells
were added.
Target Cell Lysis of CTLs and Lysis-Inhibition. Effector
cells (serially diluted PECs or spleen cells) were usually incu-
bated with target cells at 370 (final volume, 200 pl in 6-mm
wells of Linbro plates). However, when ts mutants were used,
the target cells were infected, labeled with 5'Cr, and assayed
for lysis at 340 and 390 (permissive and nonpermissive tem-
peratures, respectively). After 4 hr, each well was individually
agitated with a pasteur pipet, the entire plate was centrifuged
(450 X g, 5 min), and supernatant radioactivity (representing
51Cr released by lysed cells) was measured in a Packard Auto-
Gamma scintillation spectrometer. The sedimented cells were
dried, dissolved in 200 Ml of 1 M NaOH, and also assayed for
radioactivity. Specific lysis was defined as 100 (IR - NR/T -
NR), in which IR and NR represent percent 5'Cr release by
target cells incubated with immune and normal lymphocytes,
respectively, and T is the total target cell radioactivity
(100%).
To test the ability of antibodies to block CTL activity, target
cells were incubated (30 min, 370) with serial dilutions of var-
ious antisera, and effector cells (plus additional antiserum to
maintain the antiserum dilution) were then added at effec-
tor-to-target ratios that caused 15%-30% lysis of the targets. Cell
lysis was then assayed as described above.
Antiserum to G Protein. The envelope glycoprotein of VSV
(G protein) was extracted from sucrose-gradient purified virus
with Nonidet P40 (15). To remove contaminants, G protein
preparations were passed through Sephadex G-75 in phos-
phate-buffered saline/0.2% deoxycholate. Electrophoretic
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analysis showed that the void volume contained G protein as
monomers and dimers; it also contained trace amounts of some
cellular proteins, but the other viral proteins were not detect-
able.
Rabbits were injected once with 50 ,ug of purified G protein
in complete Freund's adjuvant and twice (3- to 4-wk intervals)
with 25 jig of G protein in incomplete adjuvant. Anti-G anti-
bodies became evident only after additional injections, at 1-
month intervals, of 50 ,ug of glutaraldehyde-crosslinked G
protein in incomplete adjuvant. The antisera at a 1:100 dilution
decreased infectivity of the test virus by four to five orders of
magnitude. Specificity was established by polyacrylamide gel
electrophoresis (in 0.1% sodium dodecyl sulfate) of immune
precipitates (16) prepared with anti-G serum and lysates of
VSV-infected cells that had been grown in [s5S]methionine (16):
about 95% of the specifically precipitated [35S]protein migrated
with G protein.
Other Antisera. Antiserum to disrupted VSV virions was
generously provided by Alice Huang, Harvard Medical School.
One sample of anti-thy 1.2 sera (AKR mice immunized with
C3H thymocytes) was a generous gift from Michael Bevan,
Massachusetts Institute of Technology; another sample was
obtained from Litton Laboratories (Bethesda, MD).
Media. For all cell-mediated cytotoxicity assays, the cells
were grown, washed, and incubated in RPMI 1640 (Gibco)
supplemented with fetal calf serum, amino acids, sodium
pyruvate, penicillin/streptomycin, and 2-mercaptoethanol as
described (14). For assays with antibody and complement, sera
were diluted and cells were washed with RPMI 1640/0.1%
gelatin.
RESULTS
Eliciting CTLs In Vivo. Cytotoxic cells that were active over
a wide range of effector/target ratios were more consistently
elicited in mice injected with UV-inactivated VSV than in those
injected with infectious virus, perhaps because proliferating
T cells are unusually vulnerable to VSV infection (17-19).
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FIG. 1. Time course of development of cytotoxic T lymphocytes. Spleen cells removed at various times after one intravenous injection of
BALB/c mice with inactivated VSV (2 X 108 PFU before and 102-103 after irradiation) were tested for ability to lyse infected P388D1 cells.
E:T, ratio of numbers of effector (spleen) to target cells in the cytotoxicity assay. (Inset) Summary of results for individual mice at E:T =
50:1.
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FIG. 2. Lysis of VSV-infected and uninfected P388D1 cells by
spleen cells (A) and PECs (B) from normal and VSV-immunized mice
at various effector/target (E:T) ratios. A, Infected P388D1 cells +
immune spleen cells or PECs; *, infected P388D1 cells + normal
spleen cells or PECs; 0, uninfected P388D1 cells + immune spleen
cells or PECs; 0, uninfected P388D1 cells + normal spleen cells or
PECs.
Preliminary studies indicated that, with UV-inactivated virus,
cytotoxic cells could be elicited by a single intravenous or in-
traperitoneal injection. Subsequent immunizations were carried
out with one injection of 2 X 108 PFU inactivated to 102-103
PFU. Spleen cells and PECs were harvested 6-8 days later,
based on the time course shown in Fig. 1. After intravenous
injection of virus, cytotoxic cells were regularly present in spleen
(Fig. 2A) but only rarely in PECs (data not shown); after in-
traperitoneal injection they were regularly present in PECs
(Fig. 2B) but only occasionally in spleen (data not shown).
Target cells were not lysed by spleen cells or PECs from
noninmunized mice. The cytotoxic cells were T cells (CTLs)
because all cytotoxic activity of spleen cells and PECs from
VSV-immunized mice was specifically eliminated by treating
the cells with anti-thy 1.2 serum (AKR antiserum to C3H thy-
mocytes) plus complement (data not shown).
H-2 Restriction of CTLs. As shown in Table 1, at an effec-
tor/target cell ratio of 50:1, CTLs from VSV-immunized
BALB/c mice and the three congenic strains caused significant
lysis only when the target cells shared at least one H-2D or H-2K
allele with the stimulator and effector cells. For example, CTLs
from immunized BALB.b (bb) mice caused specific lysis of
infected 3T3 fibroblastic targets derived from the BALB.b and
BALB.HTG (db) strains but not for the corresponding BALB/c
(dd) or BALB.k (kk) target cells. Although Table 1 shows vir-
tually no killing over the background level across H-2 differ-
ences, when the effector/target ratio was increased to 200:1,
up to 20% of the lysis observed with the homologous target was
found with H-2 different targets.
Infection of Target Cells with ts Mutants. There are two
known VSV-specified proteins associated with the surface of
infected cells: G protein found on the exterior surface of the
plasma membrane and M protein found mainly on the interior
surface. To investigate whether one or both of these proteins
are parts of the targets for CTLs, ts mutants of VSV were used.
At the nonpermissive temperature (390), tsM makes a defective
M protein that is rapidly degraded after its synthesis and tsG
makes a defective G protein that does not move to the cell
surface from its site of synthesis on intracellular membranes (6,
7).
Cells infected with tsM were specifically lysed at both re-
strictive and permissive temperature by CTLs from mice im-
munized with wild-type virus, and they were lysed to virtually
the same extent as targets infected with wild-type virus (Fig.
3 A and B). In contrast, cells infected at the nonpermissive
temperature (390) with tsG failed to serve as targets whereas,
at the same temperature, cells infected with wild-type virus
were readily lysed (Fig. 3 D). At 34°, cells infected with tsG
express the G protein normally (6, 7) and were also readily lysed
(Fig. 3 C). In corroboration of these findings, lysis of target cells
infected with wild-type VSV was completely blocked by anti-
sera to G protein as well as by antiserum to virions (Fig. 4).
DISCUSSION
The present study shows that lysis of VSV-infected cells by
CTLs from VSV-immunized mice is subject to H-2 restriction.
Similar restriction has already been well established in the
immune responses to infection by several other viruses (21-25).
The limited number of proteins specified by the VSV genome
(4-5) and the existence of mutants with biochemically defined
Table 1. H-2 restriction in lysis of 3T3 fibroblasts from congenic BALB mice
Spleen cells Targetst
from* P388D1 3T3 BALB/c 3T3 BALB.b 3T3 BALB.k 3T3 BALB.HTG
Strain Status (dd) (dd) (bb) (kk) (db)
BALB/c N 10.7 + 2.8 17.7 + 2.1 22.7 + 1.1 21.7 ± 2.7 27.8 + 1.9
I 41.7 5.8 32.1 + 6.2 25.8 + 3.5 25.7 ± 4.2 38.1 ± 2.8
BALB b N 12.2 + 3.7 16.3 + 1.7 17.5 + 3.1 15.6 ± 3.2 17.7 + 2.8BALB*b I 15.1 4.8 17.5 + 2.4 32.7 + 3.3 14.8± 1.8 29.8 3.7
N 14.8 ± 3.1 20.7 + 2.9 18.7 ± 2.4 21.0 ± 2.7 17.0 i 2.0BALB.k I 16.1 + 3.7 22.8 + 3.1 23.8 i 1.7 36.8 + 3.7 22.0 + 1.7
N 13.9 + 2.8 19.7 + 3.1 21.0 + 1.7 17.2 + 1.8 18.1 + 1.9BALB.HTG I 35.8 ± 5.1 41.7 ± 5.8 37.1 + 3.8 21.1 + 2.7 39.1 + 6.1
* Mice were immunized by one intravenous injection of UV-irradiated virus. Immune effectors (I) were spleen cells taken 7 days after the injection;
controls were normal spleen cells (N) from uninjected mice of the same strain.
t The targets, labeled with 51Cr and infected with VSV (multiplicity of infection, 25), were P388D1 cells or 3T3 fibroblasts from the indicated
strains (H-2K and H-2D alleles in parentheses), all tested at an effector/target cell radio of 50:1. Values are %51Cr released, shown as mean
± half the range of duplicates. Mean values > 30% were observed only under conditions in which requirements for H-2 restriction were met
(boldface).
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FIG. 3. Lysis ofP388D1 target cells infected with wild-type VSV, tsM (A and B), or tsG (C and D). Infected P388D1 target cells (multiplicity
of infection, 10-25) were tested at 340 (A and C) and 390 (B and D) (permissive and nonpermissive temperatures, respectively) for susceptibility
to lysis by spleen cells from mice injected intravenously with wild-type VSV or from uninjected (control) mice. A, Mutant-infected targets +
immune spleen cells; 0, wild-type VSV-infected targets + immune spleen cells; A, mutant-infected targets + normal spleen cells; 0, wild-type
VSV-infected targets + normal spleen cells. Slight lysis at high levels of effector cells in D could mean that a small proportion of the CTLs are
directed to an antigen other than G protein or, more likely, that a small amount ofG protein is present on cells infected with tsG at the nonper-
missive temperature (20).
defects (e.g., refs. 4-7) make the VSV system
promising one for identifying unambiguously the
required for CTL activity.
Cells infected by tsM were equally susceptil
45
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FIG. 4. Rabbit antisera to disrupted virions (an
purified G protein (anti-G) inhibited lysis of VSV-inf
target cells by CTLs from spleens of BALB/c mice inj
nously with irradiated wild-type virus (E:T ratio, 50:
periment, anti-G was adsorbed with 2 X 108 cells of
mouse L cells before being tested as an inhibitor. Ads
adsorbed sera at dilutions of 1:5 to 1:160 were incub
target cells before addition of effector CTLs. Uninfecl
not adsorb the anti-G antibodies (data not shown). So
line (at 42%-45% 51Cr release) represents uninhibited I
Broken horizontal line (at 17.5%) represents 51Cr relea
of spleen cells from nonimmunized mice. 0, Anti-VSV 2
serum (from rabbit 1); 0, anti-G serum (from rabbit
(from rabbit 2) after adsorption with VSV-infected L ce
rabbit serum.
a particularly CTLs at permissive (340) and nonpermissive (390) tempera-
e viral antigen tures, whereas cells infected with tsG were lysed only at the
permissive temperature (340), at which they express G protein
ble to lysis by on the cell surface. The necessity for cell surface G protein is
also suggested by the ability of antisera to G protein to block
lysis of infected cells. Recent studies of CTL lysis of cells in-
fected with recombinant and variant influenza viruses have also
pointed to particular viral proteins (hemagglutin, matrix pro-
tein) as being necessary for lysis by H-2 restricted CTLs (22,
23).
The present results are particularly significant in relation to
the general problem of identifying the cell surface antigens that
are recognized by CTLs. Genetic and serological analyses
currently provide the only approaches available for identifying
these antigens. But neither of these approaches leads to un-
equivocal results. Thus, correlations between a target cell's
genome and its susceptibility to lysis only establish linkage, not
identity, between a particular allelic product and key cell sur-
face antigens. Under some circumstances, as with the ts VSV
mutants and influenza virus recombinants, it is possible to show
that a particular cell surface molecule is essential for lysis, but
not that the molecule is itself recognized by CTLs. Likewise,
antibody blockade of lysis may be due to steric hindrance by140 160 bound antibody molecules rather than to competitive binding
of the same antigenic determinants by both the blocking anti-
iti-VSV) or to bodies and CTLs (26, 27).
Fected P388D1 There is also some uncertainty about the products of the H-2jected intrave- complex that restrict antigen recognition by syngeneic CTLs.). In one ex- In a recent study of a plasmacytoma, for instance, tumor cellsVSoV-infected that reacted perfectly well with anti-H-2 alloantibodies lost
oated with the their reactivity with allogeneic anti-H-2 CTLs (14) and with
ted L cells did H-2 syngeneic CTLs that were directed to other antigens on
Lid horizontal the tumor cells (A. H. Hale, J. H. Russell, and H. N. Eisen, un-
lysis by CTLs. published data). Studies of mutations at the H-2K and H-2D
se in presence loci of C57BL/6 and BALB/c mice also raise the possibility that
2era;*, anti-G the cell surface molecules recognized by CTLs may not be the
ells; A, normal glycoproteins recognized by anti-H-2 antibodies (27-29). In
view of all these uncertainties there is an almost complete void
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in our understanding of the molecular properties of the cell
surface antigens recognized by CTLs on syngeneic tumor cells
and on virus-infected cells.
Although genetic variants of target cells and antibody
blockade of lysis can provide valuable leads, unequivocal
identification of the antigens recognized by CTLs requires more
direct evidence, such as the demonstration that a purified
substance binds specifically to CTLs or elicits the development
of these T cells or can be used to construct particles that are
active in either capacity. Because the G protein of VSV can be
readily purified in relatively large amounts, it may prove to be
particularly helpful for developing general means for identi-
fying the antigens recognized by CTLs, including those antigens
for which genetic variants and antisera are not available.
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